What do Mar­tin Shkre­li, Gilead and Take­da have in com­mon? They all fig­ure promi­nent­ly in the new top-20 list of the world’s most ex­pen­sive drugs

Take­da is about to buy its way to a num­ber 1 spot in the top tier of drug­mak­ers field­ing the most ex­pen­sive drugs on the plan­et.

Once its $62 bil­lion Shire buy­out goes through, Take­da will be re­spon­si­ble for sell­ing three of the most ex­pen­sive drugs on the mar­ket to­day, ac­cord­ing to the lat­est list from GoodRx. And that’s more than any oth­er man­u­fac­tur­er on the rank­ing.

The drug pric­ing an­a­lysts at GoodRx de­cid­ed this year that they need­ed to dou­ble the num­ber of drugs tracked in or­der to be able to ful­ly cap­ture the grow­ing ranks of ther­a­pies that com­mand whole­sale prices of more than $25,000 a month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER